Evaxion Biotech A/S
(NASDAQ : EVAX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 8.73%147.660.0%$994.17m
AMGNAmgen, Inc. 0.87%255.261.5%$856.48m
GILDGilead Sciences, Inc. 0.51%64.801.0%$543.24m
VRTXVertex Pharmaceuticals, Inc. 1.51%273.731.9%$497.98m
REGNRegeneron Pharmaceuticals, Inc. 1.37%692.802.6%$444.80m
ILMNIllumina, Inc. 5.95%258.063.3%$337.13m
NVAXNovavax, Inc. 17.46%55.2975.7%$314.14m
BIIBBiogen, Inc. 0.97%206.201.8%$237.64m
BNTXBioNTech SE 5.57%166.960.0%$224.59m
SNSSSunesis Pharmaceuticals, Inc. 2.38%2.150.7%$150.29m
EXASEXACT Sciences Corp. 7.96%53.8317.7%$134.25m
TECHBio-Techne Corp. 5.81%386.564.5%$107.96m
TXG10X Genomics, Inc. 11.91%52.990.0%$106.79m
BMRNBioMarin Pharmaceutical, Inc. 2.68%80.974.2%$95.42m
CRSPCRISPR Therapeutics AG 5.63%58.340.6%$85.42m

Company Profile

Evaxion Biotech A/S engages in the discovery and development of novel immunotherapies for cancer and infectious diseases. It uses its proprietary AI technology, engineering expertise and drug development know-how to simulate the human immune system and generate predictive models to identify and develop efficacious immunotherapies for patients in the global market. The company was founded by Niels Iversen Møller and Andreas Holm Mattsson on August 11, 2008 and is headquartered in Hoersholm, Denmark.